Successful Treatment of Facial Pseudolymphoma With Intravenous Rituximab: A Case Report

Intravenous rituximab demonstrated significant efficacy in treating a case of refractory cutaneous pseudolymphoma that failed multiple conventional therapies, including corticosteroids, hydroxychloroquine, methotrexate, and biologics. The patient, a 42‐year‐old man, initially developed erythematous, nodular lesions on the face following dental implant surgery, which later spread and persisted despite various immunosuppressive and anti‐inflammatory treatments. Histopathological and immunohistochemical analysis confirmed B‐cell pseudolymphoma. Intravenous rituximab (500 mg weekly for 4 weeks, followed by maintenance doses) led to substantial lesion regression, with no recurrence observed after 1 year of follow‐up. This case underscores the therapeutic potential of rituximab for treatment‐resistant pseudolymphoma and highlights the need for further research into optimal treatment protocols for this rare condition.